-transparent.png){kind=logo}
Twenty patients (mean age 52 +/- 12 years, mean weight 75 +/- 15 kg) scheduled for elective myelogram or spinal anaesthesia were enrolled to determine the cerebrospinal fluid (CSF) penetration of a new expanded spectrum cephalosporin antibiotic, cefpirome (HR-810). A single 2 g intravenous dose of cefpirome was administered as a bolus between 1 and 8 h before lumbar puncture. Blood samples were collected at 15 pre-determined times and a single CSF sample was obtained at the time of lumbar puncture. Serum and CSF cefpirome concentrations were determined by high performance liquid chromatography. The mean maximal serum concentration of cefpirome was 264 +/- 76 mg/L. A mean steady-state volume of distribution of 20 +/- 4 L, clearance of 7.4 +/- 1.3 L/h, and half-life of 2.5 +/- 0.5 h were determined. Mean CSF concentrations were 0.50 +/- 0.11 mg/L at 1-2 h post dose (n = 4), 0.57 +/- 0.13 mg/L at 2-4 h post dose (n = 4), 0.76 +/- 0.34 mg/L at 4-6 h post dose (n = 7), and 0.83 +/- 0.29 mg/L at 6-8.3 h post dose (n = 5). Blood:brain barrier permeability to cefpirome may not be a limiting factor as CSF concentrations were rapidly attained. Further studies are required to determine the mechanism of cefpirome transport between plasma and CSF.
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
June 1991,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
July 1990,
Neurochirurgia,
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
November 1993,
The Journal of antimicrobial chemotherapy,
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
January 1987,
Infection,
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
November 1983,
The Journal of antimicrobial chemotherapy,
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
July 1994,
The Journal of antimicrobial chemotherapy,
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
March 1980,
The Journal of antimicrobial chemotherapy,
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
November 1984,
Antimicrobial agents and chemotherapy,
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
January 2000,
Antimicrobial agents and chemotherapy,
D E Nix, and
J H Wilton, and
N Velasquez, and
J L Budny, and
H B Lassman, and
P Mitchell, and
K Divan, and
J J Schentag
September 1986,
Antimicrobial agents and chemotherapy,
